title: Effects of navelbine and docetaxel on gene expression in lung cancer cell strains.
abstract: OBJECTIVE
  To search genes sensitivity to the anti-cancer drugs navelbine (NVB) and docetaxel (DOC) in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) cell strains.
  
  
  METHODS
  The sensitivity of 4 strains of SCLC and 6 strains of NSCLC to NVB and DOC was evaluated using the MTT assay. The expression of 1291 sensitive-related genes to the anti-cancer drugs in 10 lung cancer cell strains was measured using cDNA macroarrays and the relationship was analyzed.
  
  
  RESULTS
  In total, there were 56 (r > or = 0.4) genes sensitive to NVB and DOC. For NVB: 36 genes were sensitive to NVB, 20 co-expressed genes between the SCLC+NSCLC set and the NSCLC set; 27 expressed genes and 7 specially expressed genes in the SCLC+NSCLC set; and 29 expressed genes and 9 specially expressed genes in the NSCLC set. For DOC, 50 genes were sensitive to DOC, 12 co-expressed genes between the SCLC+NSCLC set and the NSCLC set; 24 expressed genes and 12 specially expressed genes in the SCLC+NSCLC set; and 38 expressed genes and 26 specially expressed genes in the NSCLC set. The genes sensitive to NVB and DOC in lung-cancer cell stains were mainly divided into the following 4 categories: signal transduction molecules, cell factors, transcription factors and metabolism-related enzymes and inhibitors.
  
  
  CONCLUSIONS
  There were obvious differences in genes related to NVB and DOC between SCLC and NSCLC cell strains, but the same as categories of function.
authors.affiliation: Internal Medicine of Oncology, the Third Affiliated Hospital of Harbin Medical University, Harbin 150040, China. caiwenxin76@yahoo.com.cn
authors.forename: Li
authors.initials: L
authors.lastname: Cai
authors.forename: Hai-ying
authors.initials: HY
authors.lastname: Dong
authors.forename: Guang-jie
authors.initials: GJ
authors.lastname: Sui
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D016000:Cluster Analysis; D051152:Clusterin / Q000235:genetics; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D037483:Galectin 1 / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D020128:Inhibitory Concentration 50; D008175:Lung Neoplasms / Q000235:genetics / Q000473:pathology; D008668:Metallothionein / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D043823:Taxoids / Q000494:pharmacology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000235:genetics; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077235:Vinorelbine
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D051152:Clusterin; D037483:Galectin 1; D043823:Taxoids; D019715:Tissue Inhibitor of Metalloproteinase-1; D000077143:Docetaxel; D014747:Vinblastine; D008668:Metallothionein; D000077235:Vinorelbine